Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
Ann Hematol ; 103(6): 2041-2050, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38411628

ABSTRACT

The international prognostic index (IPI) system has been widely used to predict prognosis in diffuse large B-cell lymphoma (DLBCL). However, this system categorizes DLBCL patients into four risk groups, and cannot optimize individualized prognosis. In addition, other clinicopathological factors, such as molecular aberrations, are not incorporated into the system. To partly overcome these weak points, we developed nomograms to predict individual patient survival. We also incorporated MYD88L265P and CD79BY196 mutations into the nomograms since these mutations are associated with a worse prognosis and their signaling pathways have been highlighted as a therapeutic target. We analyzed 302 DLBCL cases for which multivariate analysis by Cox proportional hazard regression was performed. Nomograms for progression-free survival (PFS) and overall survival (OS) were constructed and assessed by a concordance index (C-index). The nomograms were also evaluated using an open external dataset (n = 187). The MYD88L265P and/or CD79BY196 (MYD88/CD79B) mutation was detected in 62/302 patients. The nomograms incorporating IPI factors exhibited a C-index of 0.738 for PFS and a C-index of 0.765 for OS. The nomograms incorporating IPI factors and the MYD88/CD79B mutation showed a C-index of 0.745 for PFS and a C-index of 0.769 for OS. The nomograms we created were evaluated using an external dataset and were well validated. The present nomograms incorporating IPI factors and the MYD88/CD79B mutation have sufficient discrimination ability, and may effectively predict prognosis in DLBCL patients. The prognostic models we have presented here may help clinicians personalize prognostic assessments and clinical decisions.


Subject(s)
CD79 Antigens , Lymphoma, Large B-Cell, Diffuse , Mutation , Myeloid Differentiation Factor 88 , Nomograms , Humans , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/mortality , Lymphoma, Large B-Cell, Diffuse/diagnosis , Male , Female , Middle Aged , Myeloid Differentiation Factor 88/genetics , Aged , Adult , CD79 Antigens/genetics , Aged, 80 and over , Prognosis , Survival Rate , Young Adult , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
2.
Rinsho Ketsueki ; 65(5): 420-427, 2024.
Article in Japanese | MEDLINE | ID: mdl-38825522

ABSTRACT

There are two main types of clinical trials: industry-sponsored trials and investigator-initiated trials. Both of these, like the two sets of wheels on a car, are essential to development of treatments. Numerous clinical trials have been conducted in multiple myeloma, contributing to the development of new drugs and the current treatment landscape. Highly effective novel immunotherapies, such as bispecific antibodies and chimeric antigen receptor T-cell therapy, have emerged, and could be incorporated into the treatment landscape in the near future. However, given the improved performance of current standard therapies, the drawbacks (e.g., toxicity) of immunotherapy can be expected to outweigh the benefits (efficacy) in some patients. Therefore, clinical trials are designed to evaluate treatments stratified based on factors such as post-treatment efficacy and disease risk, and stratified treatment approaches are increasingly being considered as well as one-size-fits-all approaches to treatment development. In addition, the use of real-world data is being explored to make clinical trials more efficient. These approaches are expected to further improve the individualization and efficiency of multiple myeloma treatment.


Subject(s)
Clinical Trials as Topic , Immunotherapy , Multiple Myeloma , Multiple Myeloma/therapy , Humans , Immunotherapy/methods
3.
Eur J Neurosci ; 58(8): 3810-3826, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37641563

ABSTRACT

To enhance smooth muscle contraction and relaxation during rehabilitation and sports activities, a comprehensive understanding of the motor control mechanisms within the central nervous system is necessary. However, current knowledge on these aspects is insufficient. Therefore, this study aimed to deepen our understanding of motor controls, by investigating the alterations in corticospinal excitability within cortical motor areas related to muscle contraction and relaxation using motor imagery with a reaction time task paradigm. Transcranial magnetic stimulation was used to measure the motor-evoked potentials in the first dorsal interosseous muscle of the right hand after the 'go' signal. Static weak muscle contraction (Experiment 1: 18 healthy participants) and resting state (Experiment 2: 16 healthy participants) were applied as background factors, and a trial without motor imagery was performed as a control. Muscle contraction was maintained in the background in the contraction motor imagery. A decrease in excitability in the relaxation motor imagery task occurred compared with the control. When the muscles were at rest, an increase in excitability in the contraction motor imagery and a transient increase in excitability in the relaxation motor imagery occurred compared with the control condition. Hence, the excitability of contraction and relaxation motor imagery is characterized by a continuous increase in excitability, transient increase and subsequent decrease in excitability, respectively. These results suggest that muscle contraction sensory information in the background condition may be necessary for muscle relaxation. Matching the background conditions may be crucial when utilizing motor imagery for rehabilitation or sports training.

4.
Hematol Oncol ; 41(3): 424-433, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36426594

ABSTRACT

Indoleamine 2,3-dioxygenase 1 (IDO), an enzyme that metabolizes tryptophan (Trp) to kynurenine (Kyn), is an important microenvironmental factor suppressing antitumor immunity. Here, we investigated the clinical impact of aberrant Trp metabolism in patients with multiple myeloma (MM) treated with lenalidomide (Len) and evaluated its effects on T cell immunity ex vivo. Kyn and Trp concentrations were quantified in sera from 72 patients with relapsed or refractory MM prior to the initiation of therapy with Len plus dexamethasone (Ld). Associations of the Kyn/Trp ratio with progression-free survival (PFS) and overall survival (OS) were analyzed. The expressions of IDO in tumor and stromal cells were evaluated during co-culture, and the effects of culture medium containing low Trp and high Kyn concentrations on T cells in the presence of Len were investigated. Patients with high serum Kyn/Trp ratios (≥46.0, n = 22) had significantly shorter PFS and OS than those with low ratios (4.9 vs. 12.6 months, and 15.5 vs. 45.7 months, respectively). MM cells promoted IDO expression in stromal cells during co-culture in both a direct contact and an indirect manner. Incubation in medium with a high Kyn/Trp ratio significantly inhibited T cell cytokine production and upregulated the expression of inhibitory immune receptors. These effects were sustained even in the presence of Len. In conclusion, a high serum Kyn/Trp ratio is associated with poor prognosis in patients with MM. We propose that aberrant Trp metabolism reduces anti-tumor immunity and the efficacy of Len therapy.


Subject(s)
Multiple Myeloma , Tryptophan , Humans , Multiple Myeloma/drug therapy , Lenalidomide/therapeutic use , Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism , Kynurenine
5.
J Phys Ther Sci ; 35(4): 293-299, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37020829

ABSTRACT

[Purpose] This study aimed to examine the difference in the excitability of the primary motor cortex between initiation-predictive and non-predictive tasks, where the onset of muscle relaxation is predicted and not predicted, respectively. [Participants and Methods] Seventeen participants were asked to perform rapid muscle relaxation either through an initiation-predictive or non-predictive task. The baseline was set at 20 percent of the maximum voluntary contraction. Motor-evoked potentials and H-reflexes elicited by transcranial magnetic stimulation and median nerve electrical stimulation, respectively, were measured. The mean stimulation time from the onset of relaxation was calculated, and the motor-evoked potentials and Hoffmann's reflexes elicited during the first (immediately before relaxation) and second half (long before relaxation) were compared. [Results] The amplitude of the motor-evoked potential significantly increased in both initiation-predictive and non-predictive tasks when compared to the baseline, indicating increased excitability of the primary motor cortex. The motor-evoked potential from the initiation-non-predictive task, but not the initiation-predictive task, was associated with increased excitability of the primary motor cortex immediately before relaxation. [Conclusion] Variations in the predictability of motor movements are associated with changes in muscle relaxation control in the central nervous system.

6.
J Phys Ther Sci ; 35(4): 281-288, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37020831

ABSTRACT

[Purpose] This study aimed to investigate how the speed alteration task, which gradually increases or conversely decreases walking speed, affected walking stability. [Participants and Methods] Thirteen healthy young adults performed two walking tasks as follows: the speed alteration task, in which the walking speed was gradually increased or decreased, and the speed constant task, in which the walking speed was maintained at a comfortable level. Before and after each task, the Timed Up and Go test was performed to analyze time, walking speed, and trajectory. The overall score of the Timed Up and Go test, as well as the scores of the three major segments (i.e., forward, turning around, and return), and nine subsegments, were calculated and analyzed. [Results] During the speed alteration task, parameters including time and walking speed of the Timed Up and Go test were significantly improved. Also, the same parameters increased significantly in the forward and return segments. These increases were also observed in the first subsegment of the forward segment and the second subsegment of the return segment. [Conclusion] The speed alteration task improved walking stability, so it could be used in gait training to improve walking stability.

7.
Jpn J Clin Oncol ; 52(9): 966-974, 2022 Sep 18.
Article in English | MEDLINE | ID: mdl-35830865

ABSTRACT

Multiple myeloma is a cancer of plasma cells; the incidence rate of multiple myeloma is high among older adults. Although significant advances have been made in the clinical management of multiple myeloma driven by the introduction of novel drugs, such as proteasome inhibitors, immuno- modulators and antibodies, multiple myeloma remains incurable. Hence, the current therapeutic goal for multiple myeloma is to achieve long-term survival while maintaining a good quality of life. In this context, personalized treatment to balance the efficacy and safety of therapies is important, especially for older adults as they display diverse physical, cognitive or organ functioning. Furthermore, old age is also often associated with frailty. Several tools for evaluating frailty in older adults with multiple myeloma are now available, and frail patients defined by these tools have shown a poor prognosis and more treatment-related toxicities. In addition, it is important to evaluate other factors, such as the International Staging System, high-risk chromosomal abnormalities and treatment response, to predict the clinical course of patients. Further investigations are required to determine how these factors can optimize the treatment for multiple myeloma. In this review, we present a detailed account on the developments and issues related to the current treatment approaches for older adults with newly diagnosed multiple myeloma. We also discuss the ongoing phase III clinical study conducted by the lymphoma study group of the Japan Clinical Oncology Group, which targeted older adults with newly diagnosed multiple myeloma.


Subject(s)
Frailty , Multiple Myeloma , Aged , Frailty/diagnosis , Humans , Japan , Multiple Myeloma/diagnosis , Multiple Myeloma/drug therapy , Proteasome Inhibitors/therapeutic use , Quality of Life
8.
Eur J Neurosci ; 54(6): 6123-6134, 2021 09.
Article in English | MEDLINE | ID: mdl-34328240

ABSTRACT

This study examined the effect of temporal changes in corticospinal excitability in motor imagery (MI) and the effect of real-time guides for MI on excitability changes. The MI task involved wrist flexion and motor evoked potentials using transcranial magnetic stimulation were recorded and examined from the flexor carpi radialis. Ballistic (momentary MI) and tonic (continuous MI) conditions were used, and the duration of each MI was different. In Experiment 1, each MI task was performed using an acoustic trigger. In Experiment 2, a real-time guide was presented on a computer screen, which provided a visual indication of the onset and duration of the MI task through via moving dots on the screen. The results indicate that the corticospinal excitability changed differently, depending on the duration of MI. Additionally, with real-time guides, the change in corticospinal excitability became clearer. Thus, corticospinal excitability changes due to the temporal specificities of MI, as well as with actual motor output. Moreover, if MI is actively performed without a guide, it is likely to show an unintended change in corticospinal excitability. It is suggested that when MI is performed with visual guide, the excitatory changes of the corticospinal tract might be different from the actual motor output. Therefore, when using MI for mental practices, it is possible to improve the effect of a guide for MI, such as a visual indicator for motor output. Additionally, when examining neural activities in MI, it may be necessary to consider the characteristics of motion performed by MI.


Subject(s)
Evoked Potentials, Motor , Imagination , Electromyography , Muscle, Skeletal , Pyramidal Tracts , Transcranial Magnetic Stimulation
9.
Appl Environ Microbiol ; 87(2)2021 01 04.
Article in English | MEDLINE | ID: mdl-33158893

ABSTRACT

Bakanae disease, caused by Fusarium fujikuroi, is an economically important seed-borne disease of rice. F. fujikuroi is horizontally transmitted to rice flowers and vertically transmitted to the next generation via seeds. The fungus induces typical symptoms such as abnormal tissue elongation and etiolation. Sanitation of seed farms and seed disinfection are the only effective means to control bakanae disease at present; however, the efficacy of these methods is often insufficient. Therefore, alternative and innovative control methods are necessary. We developed a novel method for applying nonpathogenic fusaria as biocontrol agents by spraying spore suspensions onto rice flowers to reduce the incidence of seed-borne bakanae. We visualized the interaction between Fusarium commune W5, a nonpathogenic fusarium, and Fusarium fujikuroi using transformants expressing two different fluorescent proteins on/in rice plants. W5 inhibited hyphal extension of F. fujikuroi on/in rice flowers and seedlings, possibly by competing with the pathogen, and survived on/in rice seeds for at least 6 months.IMPORTANCE We demonstrated that a spray treatment of rice flowers with the spores of nonpathogenic fusaria mimicked the disease cycle of the seed-borne bakanae pathogen Fusarium fujikuroi and effectively suppressed the disease. Spray treatment of nonpathogenic fusaria reduced the degree of pathogen invasion of rice flowers and vertical transmission of the pathogen to the next plant generation via seeds, thereby controlling the bakanae disease. The most promising isolate, F. commune W5, colonized seeds and seedlings via treated flowers and successfully inhibited pathogen invasion, suggesting that competition with the pathogen was the mode of action. Seed-borne diseases are often controlled by seed treatment with chemical fungicides. Establishing an alternative method is a pressing issue from the perspectives of limiting fungicide resistance and increasing food security. This work provides a potential solution to these issues using a novel application technique to treat rice flowers with biocontrol agents.


Subject(s)
Flowers/microbiology , Fusarium , Oryza/microbiology , Pest Control, Biological , Plant Diseases/prevention & control , Spores, Fungal
10.
Eur J Haematol ; 107(1): 157-165, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33905571

ABSTRACT

OBJECTIVES: In this study, we aimed to determine the clinicopathological factors influencing the treatment-free period in patients with follicular lymphoma (FL) using a watch-and-wait (WW) strategy. METHODS: We retrospectively assessed histopathological parameters of 82 patients with FL. RESULTS: The median time from diagnosis to WW discontinuation was 62 months (range, 3-138), and median follow-up was 86 months (range, 3-183). Intermediate or high-risk Follicular Lymphoma International Prognostic Index score (P = .012), non-duodenal-type (P = .011), higher numbers of interfollicular CD4+ (P = .038) and intrafollicular FOXP3+ cells (P = .024) in the tumor microenvironment, and Ki-67 index ≥10% (P = .031) were significant adverse factors for WW discontinuation in univariate analyses. CONCLUSION: Patients with adverse factors for WW discontinuation should be carefully observed during follow-up.


Subject(s)
Lymphoma, Follicular/diagnosis , Tumor Microenvironment , Watchful Waiting , Adult , Aged , Aged, 80 and over , Biomarkers , Cell Transformation, Neoplastic , Disease Progression , Female , Humans , Incidence , Lymphoma, Follicular/epidemiology , Lymphoma, Follicular/therapy , Male , Middle Aged , Models, Statistical , Predictive Value of Tests , Prognosis , Retrospective Studies , Rituximab/pharmacology , Time Factors , Treatment Outcome
11.
Eur J Haematol ; 106(2): 213-220, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33098704

ABSTRACT

OBJECTIVES: This study aimed to evaluate the outcomes of local radiotherapy (LRT) in patients with histologic transformation (HT) following rituximab-containing chemotherapy. METHODS: We retrospectively analysed 92 patients with biopsy-confirmed HT undergoing rituximab-containing chemotherapy at our institution between 2003 and 2015. RESULTS: Of the 36 patients with limited-stage disease at diagnosis of HT, 29 (78%) received LRT. The estimated 5-year progression-free survival (PFS) rate was significantly better in patients who underwent LRT than in those who did not (93% and 42%, respectively; P < 0.05). Multivariate analyses employing age, sex, performance status, LRT and treatment response demonstrated that LRT was an independent prognostic factor for PFS (hazard ratio [HR]: 11.8; 95% confidence interval [CI]: 1.28-108.1; P < 0.05). Of the 32 patients who underwent LRT for HT lesion treatment, 31 (97%) did not show disease progression within radiation fields; among them, 27 patients (84%) survived without disease progression during the follow-up period. One patient developed hypothyroidism due to LRT; the others had no acute or late-onset complications of LRT. CONCLUSIONS: Our data support the recommendation of LRT for HT lesion treatment following rituximab-containing chemotherapy in select patients with localised HT, as a rational treatment approach with potentially limited toxicity.


Subject(s)
Lymphoma, B-Cell/diagnosis , Lymphoma, B-Cell/therapy , Radiotherapy, Adjuvant , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemoradiotherapy , Combined Modality Therapy , Humans , Lymphoma, B-Cell/mortality , Middle Aged , Neoplasm Grading , Neoplasm Staging , Positron Emission Tomography Computed Tomography , Prognosis , Radiotherapy, Adjuvant/methods , Retrospective Studies , Rituximab/administration & dosage , Treatment Outcome
12.
Somatosens Mot Res ; 37(4): 313-319, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33064045

ABSTRACT

PURPOSE: Mechanisms underlying the somatosensory temporal discrimination threshold and its relationship with motor control have been reported; however, little is known regarding the change in temporal processing of tactile information during motor learning. We investigated the somatosensory temporal discrimination threshold changes during motor learning in a feedback-control task. MATERIALS AND METHODS: We included 15 healthy individuals. The somatosensory temporal discrimination threshold was measured on the index finger. A 10-session coin rotation task was performed, with 2 min' training per session. The coin rotation scores were determined through tests (continuous coin rotation at 180° at maximum speed for 10 s). The coin rotation test score and the somatosensory temporal discrimination threshold were determined at baseline and after 5 and 10 sets of training, as follows: pre-test; training5set (1 set × 5); post-test5block; training5set (1 set × 5); and post-test10block. The coin rotation score and the somatosensory temporal discrimination threshold were compared between the tests. The latter was also compared between the right (the within-subject control) and left fingers. RESULTS: The coin rotation score showed significant differences among all tests. In the somatosensory temporal discrimination threshold, there was a significant difference between the pre-test and post-test5block values, pre-test and post-test10block values of the left side and between the right and left sides in the post-test5block and the post-test10block values. CONCLUSIONS: The somatosensory temporal discrimination threshold decreased along with task-performance progress following motor learning during a feedback-control task.


Subject(s)
Discrimination, Psychological , Time Perception , Fingers , Humans , Somatosensory Cortex , Touch
13.
Rinsho Ketsueki ; 61(9): 1297-1305, 2020.
Article in Japanese | MEDLINE | ID: mdl-33162529

ABSTRACT

Novel drugs, such as proteasome inhibitors, immunomodulators, and antibody drugs, have been consistently developed, and several standard treatment regimens were approved for elderly patients with multiple myeloma who are ineligible for autologous transplantation. Meanwhile, the clinical characteristics of elderly patients are more diverse than those of younger patients in terms of various factors, such as cognitive, mental, or social functions as well as physical or organ functions. Therefore, it is difficult to implement a standard treatment regimen to all elderly patients with a one-size-fits-all approach. Furthermore, it is important to evaluate the diversity of elderly patients as objectively as possible by evaluating organ functions and frailty in accordance with geriatric assessment, which helps determine the treatment plan. In addition, it is also ideal to select the treatment after considering the factors associated with tumors, such as the presence or absence of unfavorable chromosomal abnormalities.


Subject(s)
Chromosome Aberrations , Multiple Myeloma , Proteasome Inhibitors , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Humans , Multiple Myeloma/drug therapy , Multiple Myeloma/genetics , Proteasome Inhibitors/therapeutic use , Transplantation, Autologous
14.
Ann Hematol ; 98(7): 1675-1687, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30923996

ABSTRACT

Translocation (11;18)(q21;q21) is found in mucosa-associated lymphoid tissue (MALT) lymphoma, resulting in API2/MALT1 gene fusion. It is known that t(11;18)-positive MALT lymphoma shows a tendency to disseminate and be resistant to Helicobacter pylori eradication by antibiotics. However, the prognostic features including recurrence and histological transformation (HT) remain unknown. We conducted a single-institute retrospective analysis of 464 patients with newly diagnosed MALT lymphoma, evaluating the impact of t(11;18) on clinical outcomes. One hundred and six patients were screened for the translocation by fluorescence in situ hybridization and/or reverse transcriptase-polymerase chain reaction. Of these patients, 26 patients (25%) were diagnosed as MALT lymphoma with t(11;18). The patients had a significantly shortened progression-free survival (PFS at 10 years; 26% v 57%; P = 0.004) compared to those without t(11;18). However, this did not translate into overall survival or incidence of HT. We confirmed previous reports stating that t(11;18)-positive MALT lymphoma showed disseminated disease and refractoriness to H. pylori eradication therapy. Patients with t(11;18) had more frequent monoclonal gammopathy, especially of IgM subtype (31% v 8%; P = 0.008), some of which developed class switch. These findings characterize the features of t(11;18)-positive MALT lymphoma, suggesting that it comprises a distinct clinical entity of MALT lymphoma.


Subject(s)
Chromosomes, Human, Pair 11/genetics , Chromosomes, Human, Pair 18/genetics , Lymphoma, B-Cell, Marginal Zone , Translocation, Genetic , Adolescent , Adult , Aged , Aged, 80 and over , Child , Disease-Free Survival , Female , Follow-Up Studies , Humans , In Situ Hybridization, Fluorescence , Lymphoma, B-Cell, Marginal Zone/genetics , Lymphoma, B-Cell, Marginal Zone/mortality , Male , Middle Aged , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate
15.
Somatosens Mot Res ; 36(2): 109-115, 2019 06.
Article in English | MEDLINE | ID: mdl-31092131

ABSTRACT

Voluntary motor drive is an important central command that descends via the corticospinal tract to initiate muscle contraction. When electrical stimulation (ES) is applied to an antagonist or agonist muscle, it changes the agonist muscle's representative motor cortex and thus its voluntary motor drive. In this study, we used a reaction time task to compare the effects of weak and strong ES of the antagonist or agonist muscle during the premotor period of a wrist extension. We recorded motor evoked potentials (MEPs) induced by transcranial magnetic stimulation (TMS) that was applied to the extensor carpi radialis (ECR; agonist) and flexor carpi radialis (FCR; antagonist). When stronger ES intensities were applied to the antagonist, the MEP control ratio in the ECR significantly increased during the premotor time. Furthermore, the MEP control ratio with stronger antagonist ES intensity was significantly larger than that in the agonist for the same ES intensity. In the FCR, the MEP control ratio was also significantly greater at the strong ES intensity than at the weak ES intensity. Furthermore, the MEP control ratio in the antagonist with a strong ES intensity was significantly larger than that in the agonist with the same ES intensity. These results suggest that agonist corticomotor excitability might be enhanced by ES of the antagonist, which in turn strongly activates the descending motor system in the preparation of agonist contraction.


Subject(s)
Evoked Potentials, Motor/physiology , Motor Cortex/physiology , Muscle Contraction/physiology , Muscle, Skeletal/physiology , Transcranial Magnetic Stimulation/methods , Acoustic Stimulation/methods , Adult , Female , Humans , Isometric Contraction/physiology , Male , Random Allocation , Young Adult
16.
Pathol Int ; 69(7): 392-397, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31328350

ABSTRACT

Epstein-Barr virus (EBV) infection is associated with pathogenesis of various cancers, including extranodal natural killer/T-cell lymphoma, nasal type (ENKL). ENKL tumor cells are positive for EBV-encoded RNA1 (EBER1), which is the most useful marker to identify ENKL tumor cells in histopathology. Currently, EBER1 in situ hybridization (ISH) is recommended to evaluate bone marrow (BM) involvement of ENKL. However, the actual burden of EBER1-positive cells in normal BM specimens remains unclear. In the present study, we performed EBER1 ISH on 111 BM specimens, which were obtained during an initial staging procedure in patients with EBV-negative cancers and were also negative for BM involvement. One or more EBER1-positive cells per whole specimen were observed in 38 specimens (34%). The number of EBER1-positive cells was distributed as follows: single positive cell, n = 17; two positive cells, n = 13; three positive cells, n = 3; and four positive cells, n = 5. These findings suggest that four or fewer EBER1-positive cells can be observed in BM specimens of patients with non-EBV-related cancers. The clinical implications of a small number of EBER1-positive cells in BM specimens of patients with ENKL should be evaluated in further studies.


Subject(s)
Bone Marrow/virology , Epstein-Barr Virus Infections/virology , Herpesvirus 4, Human/genetics , RNA, Bacterial/genetics , Adult , Aged , Female , Humans , Lymphoma/pathology , Lymphoma/virology , Male , Middle Aged , Polymerase Chain Reaction/methods , RNA, Viral , Sarcoma/pathology , Sarcoma/virology , Soft Tissue Neoplasms/pathology , Soft Tissue Neoplasms/virology , Young Adult
18.
BMC Psychiatry ; 18(1): 274, 2018 09 03.
Article in English | MEDLINE | ID: mdl-30176881

ABSTRACT

BACKGROUND: Approximately one-third of schizophrenia patients eventually develop treatment-resistant schizophrenia (TRS). Although the time course of TRS development varies from patient to patient, the details of these variations have not been clarified. The present study compared the duration of time required to achieve control of the first-episode psychosis (FEP) between patients who went on to develop TRS and those who did not, in order to determine whether a bifurcation point exists for the transition to TRS. METHODS: The present study included 271 schizophrenia patients. Based on the clinical assessment, each patient was assigned to a TRS (n = 79) or Non-TRS group (n = 182). Clinical factors relating to FEP treatment such as the duration of initial hospital admission and the degree of improvement were retrospectively identified. RESULTS: There was no significant difference in the duration of initial hospital admission (defined as the time from treatment introduction to successful discharge) between the two groups (mean of 87.9 days for TRS vs. 53.3 days for Non-TRS). The degree of improvement during initial hospital admission of the TRS group was significantly lower than that of the Non-TRS group (Global Assessment of Functioning (GAF) of 50 points for TRS vs. 61 points for Non-TRS). Approximately half of the TRS patients showed an acute onset pattern and longer hospital admission (mean 169 days) for their FEP. The other half of TRS patients needed no hospital admission, indicating an insidious onset pattern with no clear psychotic episode and treatment introduction without hospital admission. CONCLUSIONS: Future TRS patients can have difficulty in improvement during their FEP. There appear to be two distinct patterns for the development of TRS. One pattern is characterized by refractory positive symptoms and a longer period to control the first psychosis; the other shows latent or insidious onset and poor response to the initial treatment.


Subject(s)
Psychotic Disorders/psychology , Psychotic Disorders/therapy , Schizophrenia/therapy , Schizophrenic Psychology , Severity of Illness Index , Adult , Antipsychotic Agents/therapeutic use , Cohort Studies , Cross-Sectional Studies , Female , Follow-Up Studies , Hospitalization , Humans , Male , Retrospective Studies , Risk Factors , Secondary Prevention/methods
20.
Ann Hematol ; 95(2): 279-85, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26555284

ABSTRACT

Our goal was to evaluate the usefulness of labial salivary gland (LSG) biopsy for diagnosing immunoglobulin light chain (AL) amyloidosis, by comparing bone marrow and skin biopsies in the same patient population. This retrospective study included 34 consecutive patients who showed evidence of monoclonal proteins and symptoms considered to be due to amyloidosis, and who underwent a tissue biopsy from LSG between January 2005 and December 2012 at Nagoya City University Hospital. All samples of superficial tissues, including LSG, bone marrow, and skin, were independently evaluated as having amyloid deposits by a central review, which was blind to clinical information. An AL amyloidosis diagnosis was based on evidence of amyloid deposition in any biopsied tissue. Eighteen patients were diagnosed with AL amyloidosis. The sensitivity for detecting amyloid deposition was highest in biopsies of LSG at 89 %, followed by 77 % for bone marrow, and 72 % for skin. Amyloid deposition was detected in at least one superficial tissue of all the 18 patients. An LSG biopsy may be appropriate as a first-choice procedure to diagnose AL amyloidosis. Multiple biopsies of superficial tissues, including LSG, bone marrow, and skin, are recommended to increase the sensitivity for diagnosing AL amyloidosis.


Subject(s)
Amyloidosis/diagnosis , Immunoglobulin Light Chains/analysis , Labial Frenum/pathology , Salivary Glands, Minor/pathology , Adult , Aged , Aged, 80 and over , Amyloidosis/epidemiology , Biopsy , Female , Humans , Immunoglobulin Light-chain Amyloidosis , Male , Middle Aged , Retrospective Studies , Salivary Glands/pathology , Single-Blind Method
SELECTION OF CITATIONS
SEARCH DETAIL